NCT03187314View on ClinicalTrials.gov

Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
Esophageal NeoplasmsEsophageal DiseasesEsophageal Squamous Cell Carcinoma
Interventions
DRUG

Radiation

RT to 60 Gy, 5 x per week，for 6 weeks. Radiation begun the day after the first dose of SHR-1210

DRUG

SHR-1210

SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.

Trial Locations (1)

310002

Hangzhou Cancer Hospital, Hangzhou

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Hangzhou Cancer Hospital

OTHER

NCT03187314 - Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer | Biotech Hunter | Biotech Hunter